Global Wound Care Biologics Industry to reach USD 2.9 billion by 2025.
Global Wound Care Biologics Industry valued approximately USD 1.2 billion in 2016 is anticipated to grow with a healthy growth rate of more than 10.1% over the forecast period 2019-2025. The driving factor for the wound biological Industry is the rising prevalence of chronic wounds such as diabetic foot ulcers, leg ulcers, as well as; increasing incidents of burns; and growing number of fire accidents. and increasing harmful accidents involving use of acid, skin diseases, and surge in the number of body surgeries are likely to pump-up the global wound biologics Industry during the forecast period.
The objective of the study is to define Industry sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the Industry. Additionally, the report shall also incorporate available opportunities in micro Industrys for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.
Wound Care Biologics Industry Share and Size by 2019-2025
Wound Care Biologics Market Segmentation:
By Wound Type
* Surgical and Traumatic Wounds
By End User
* Burn Centers and Wound Clinics
* North America
- Rest of Europe
- Rest of Asia-Pacific
- Latin America
- Middle East & Africa
Major Market Players in Wound Care Biologics Market are as follows:
Smith & Nephew plc.
- Company Overview
- Financial Overview
- Product Overview
- Current Development
Integra Life Sciences Corporation
B. Braun Melsungen AG
Mölnlycke Health Care AB
, Hill-Rom Holdings, Inc.
, Cardinal Health,
Acelity L.P., Inc.,
BSN medical (Svenska Cellulosa Aktiebolaget SCA),